Hepatitis C virus: Epidemiology and clinical features of related cancer

Albert Ndzengue, Tae Hyo Kim, Abdirashid M. Shire, Lewis Rowland Roberts

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Hepatitis C virus (HCV) affects about 3 % of the world population. The region with the highest prevalence is Africa with a prevalence of 5.3 %. Genotype 1 is the most commonly encountered of the six viral genotypes. With the implementation of testing of blood products in the early 1990s, injection drug use and transmission in health and para-health care settings are now the main mechanisms of infection. HCV infection is mostly asymptomatic and diagnosed at a chronic stage by detection of anti-HCV antibodies in the blood. Nucleic acid testing confirms active HCV infection. Chronic HCV is complicated by liver cirrhosis in 20-30 % of cases. Cirrhosis is a precursor condition for hepatocellular carcinoma. The risk of hepatocellular carcinoma is increased by 17- to 20-fold in chronic HCV patients and HCV causes 20-30 % of all liver cancers worldwide. The combination of pegylated-Interferon/Ribavirin is still the standard of care for chronic HCV-infected patients who are eligible for antiviral therapy. The addition of a protease inhibitor to pegylated-Interferon/Ribavirin combination improves the rate of sustained virological response (SVR) in patients infected with HCV genotype 1. Protease inhibitors are associated with numerous side effects and alternative therapies may soon become available. HCC is the third most common cause of cancer-related death worldwide. HCV-induced HCC is expected to become the dominant cause of liver cancers as vaccination against HBV is being implemented in almost all countries. HCV-induced HCC disproportionately affects low resource countries. HCV-induced HCC mostly develops in the cirrhotic liver with transformation of regenerative nodules into dysplastic nodules and then to HCC. Death in patients with advanced HCC mostly occurs by progression to liver failure. Ultrasonographic surveillance of cirrhotics for HCC has contributed to early diagnosis of HCC. New nodules detected by ultrasonography can be confirmed with high specificity by the finding of arterial enhancement and portal venous or venous phase washout on dynamic contrast enhanced CT or MRI. The Barcelona Clinic Liver Cancer (BCLC) staging system stratifies HCC into stages of increasing severity each with its recommended treatment. The shortcoming of this staging is the heterogeneity of patients with intermediate stage disease, leading to a lack of uniformity in the treatments applied to these patients. Liver transplantation is associated with the best survival outcomes for patients with HCV-induced HCC, but graft loss can occur due to recurrence of chronic HCV in the transplanted liver. The 5-year survival of HCV-induced HCC after liver resection ranges from 40 to 70 %, but is marked by tumor recurrence rates of up to 75 % at 5 years, due to the development of de novo tumors in the residual cirrhotic liver. The best strategy to prevent HCV-induced HCC is to prevent HCV infection and to treat chronic infection at the earliest opportunity to mitigate the risk of progression to cirrhosis.

Original languageEnglish (US)
Title of host publicationViruses and Human Cancer
PublisherSpringer New York
Pages87-112
Number of pages26
Volume9781493908707
ISBN (Print)9781493908707, 1493908693, 9781493908691
DOIs
StatePublished - Mar 1 2014

Fingerprint

Hepacivirus
Epidemiology
Neoplasms
Chronic Hepatitis C
Virus Diseases
Liver Neoplasms
Ribavirin
Liver
Genotype
Protease Inhibitors
Interferons
Hepatocellular Carcinoma
Fibrosis
Recurrence
Hepatitis C Antibodies
Survival
Neoplasm Staging
Liver Failure
Residual Neoplasm
Standard of Care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ndzengue, A., Kim, T. H., Shire, A. M., & Roberts, L. R. (2014). Hepatitis C virus: Epidemiology and clinical features of related cancer. In Viruses and Human Cancer (Vol. 9781493908707, pp. 87-112). Springer New York. https://doi.org/10.1007/978-1-4939-0870-7_5

Hepatitis C virus : Epidemiology and clinical features of related cancer. / Ndzengue, Albert; Kim, Tae Hyo; Shire, Abdirashid M.; Roberts, Lewis Rowland.

Viruses and Human Cancer. Vol. 9781493908707 Springer New York, 2014. p. 87-112.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ndzengue, A, Kim, TH, Shire, AM & Roberts, LR 2014, Hepatitis C virus: Epidemiology and clinical features of related cancer. in Viruses and Human Cancer. vol. 9781493908707, Springer New York, pp. 87-112. https://doi.org/10.1007/978-1-4939-0870-7_5
Ndzengue A, Kim TH, Shire AM, Roberts LR. Hepatitis C virus: Epidemiology and clinical features of related cancer. In Viruses and Human Cancer. Vol. 9781493908707. Springer New York. 2014. p. 87-112 https://doi.org/10.1007/978-1-4939-0870-7_5
Ndzengue, Albert ; Kim, Tae Hyo ; Shire, Abdirashid M. ; Roberts, Lewis Rowland. / Hepatitis C virus : Epidemiology and clinical features of related cancer. Viruses and Human Cancer. Vol. 9781493908707 Springer New York, 2014. pp. 87-112
@inbook{930b58d0218e442ab1429fde16a6f651,
title = "Hepatitis C virus: Epidemiology and clinical features of related cancer",
abstract = "Hepatitis C virus (HCV) affects about 3 {\%} of the world population. The region with the highest prevalence is Africa with a prevalence of 5.3 {\%}. Genotype 1 is the most commonly encountered of the six viral genotypes. With the implementation of testing of blood products in the early 1990s, injection drug use and transmission in health and para-health care settings are now the main mechanisms of infection. HCV infection is mostly asymptomatic and diagnosed at a chronic stage by detection of anti-HCV antibodies in the blood. Nucleic acid testing confirms active HCV infection. Chronic HCV is complicated by liver cirrhosis in 20-30 {\%} of cases. Cirrhosis is a precursor condition for hepatocellular carcinoma. The risk of hepatocellular carcinoma is increased by 17- to 20-fold in chronic HCV patients and HCV causes 20-30 {\%} of all liver cancers worldwide. The combination of pegylated-Interferon/Ribavirin is still the standard of care for chronic HCV-infected patients who are eligible for antiviral therapy. The addition of a protease inhibitor to pegylated-Interferon/Ribavirin combination improves the rate of sustained virological response (SVR) in patients infected with HCV genotype 1. Protease inhibitors are associated with numerous side effects and alternative therapies may soon become available. HCC is the third most common cause of cancer-related death worldwide. HCV-induced HCC is expected to become the dominant cause of liver cancers as vaccination against HBV is being implemented in almost all countries. HCV-induced HCC disproportionately affects low resource countries. HCV-induced HCC mostly develops in the cirrhotic liver with transformation of regenerative nodules into dysplastic nodules and then to HCC. Death in patients with advanced HCC mostly occurs by progression to liver failure. Ultrasonographic surveillance of cirrhotics for HCC has contributed to early diagnosis of HCC. New nodules detected by ultrasonography can be confirmed with high specificity by the finding of arterial enhancement and portal venous or venous phase washout on dynamic contrast enhanced CT or MRI. The Barcelona Clinic Liver Cancer (BCLC) staging system stratifies HCC into stages of increasing severity each with its recommended treatment. The shortcoming of this staging is the heterogeneity of patients with intermediate stage disease, leading to a lack of uniformity in the treatments applied to these patients. Liver transplantation is associated with the best survival outcomes for patients with HCV-induced HCC, but graft loss can occur due to recurrence of chronic HCV in the transplanted liver. The 5-year survival of HCV-induced HCC after liver resection ranges from 40 to 70 {\%}, but is marked by tumor recurrence rates of up to 75 {\%} at 5 years, due to the development of de novo tumors in the residual cirrhotic liver. The best strategy to prevent HCV-induced HCC is to prevent HCV infection and to treat chronic infection at the earliest opportunity to mitigate the risk of progression to cirrhosis.",
author = "Albert Ndzengue and Kim, {Tae Hyo} and Shire, {Abdirashid M.} and Roberts, {Lewis Rowland}",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/978-1-4939-0870-7_5",
language = "English (US)",
isbn = "9781493908707",
volume = "9781493908707",
pages = "87--112",
booktitle = "Viruses and Human Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Hepatitis C virus

T2 - Epidemiology and clinical features of related cancer

AU - Ndzengue, Albert

AU - Kim, Tae Hyo

AU - Shire, Abdirashid M.

AU - Roberts, Lewis Rowland

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Hepatitis C virus (HCV) affects about 3 % of the world population. The region with the highest prevalence is Africa with a prevalence of 5.3 %. Genotype 1 is the most commonly encountered of the six viral genotypes. With the implementation of testing of blood products in the early 1990s, injection drug use and transmission in health and para-health care settings are now the main mechanisms of infection. HCV infection is mostly asymptomatic and diagnosed at a chronic stage by detection of anti-HCV antibodies in the blood. Nucleic acid testing confirms active HCV infection. Chronic HCV is complicated by liver cirrhosis in 20-30 % of cases. Cirrhosis is a precursor condition for hepatocellular carcinoma. The risk of hepatocellular carcinoma is increased by 17- to 20-fold in chronic HCV patients and HCV causes 20-30 % of all liver cancers worldwide. The combination of pegylated-Interferon/Ribavirin is still the standard of care for chronic HCV-infected patients who are eligible for antiviral therapy. The addition of a protease inhibitor to pegylated-Interferon/Ribavirin combination improves the rate of sustained virological response (SVR) in patients infected with HCV genotype 1. Protease inhibitors are associated with numerous side effects and alternative therapies may soon become available. HCC is the third most common cause of cancer-related death worldwide. HCV-induced HCC is expected to become the dominant cause of liver cancers as vaccination against HBV is being implemented in almost all countries. HCV-induced HCC disproportionately affects low resource countries. HCV-induced HCC mostly develops in the cirrhotic liver with transformation of regenerative nodules into dysplastic nodules and then to HCC. Death in patients with advanced HCC mostly occurs by progression to liver failure. Ultrasonographic surveillance of cirrhotics for HCC has contributed to early diagnosis of HCC. New nodules detected by ultrasonography can be confirmed with high specificity by the finding of arterial enhancement and portal venous or venous phase washout on dynamic contrast enhanced CT or MRI. The Barcelona Clinic Liver Cancer (BCLC) staging system stratifies HCC into stages of increasing severity each with its recommended treatment. The shortcoming of this staging is the heterogeneity of patients with intermediate stage disease, leading to a lack of uniformity in the treatments applied to these patients. Liver transplantation is associated with the best survival outcomes for patients with HCV-induced HCC, but graft loss can occur due to recurrence of chronic HCV in the transplanted liver. The 5-year survival of HCV-induced HCC after liver resection ranges from 40 to 70 %, but is marked by tumor recurrence rates of up to 75 % at 5 years, due to the development of de novo tumors in the residual cirrhotic liver. The best strategy to prevent HCV-induced HCC is to prevent HCV infection and to treat chronic infection at the earliest opportunity to mitigate the risk of progression to cirrhosis.

AB - Hepatitis C virus (HCV) affects about 3 % of the world population. The region with the highest prevalence is Africa with a prevalence of 5.3 %. Genotype 1 is the most commonly encountered of the six viral genotypes. With the implementation of testing of blood products in the early 1990s, injection drug use and transmission in health and para-health care settings are now the main mechanisms of infection. HCV infection is mostly asymptomatic and diagnosed at a chronic stage by detection of anti-HCV antibodies in the blood. Nucleic acid testing confirms active HCV infection. Chronic HCV is complicated by liver cirrhosis in 20-30 % of cases. Cirrhosis is a precursor condition for hepatocellular carcinoma. The risk of hepatocellular carcinoma is increased by 17- to 20-fold in chronic HCV patients and HCV causes 20-30 % of all liver cancers worldwide. The combination of pegylated-Interferon/Ribavirin is still the standard of care for chronic HCV-infected patients who are eligible for antiviral therapy. The addition of a protease inhibitor to pegylated-Interferon/Ribavirin combination improves the rate of sustained virological response (SVR) in patients infected with HCV genotype 1. Protease inhibitors are associated with numerous side effects and alternative therapies may soon become available. HCC is the third most common cause of cancer-related death worldwide. HCV-induced HCC is expected to become the dominant cause of liver cancers as vaccination against HBV is being implemented in almost all countries. HCV-induced HCC disproportionately affects low resource countries. HCV-induced HCC mostly develops in the cirrhotic liver with transformation of regenerative nodules into dysplastic nodules and then to HCC. Death in patients with advanced HCC mostly occurs by progression to liver failure. Ultrasonographic surveillance of cirrhotics for HCC has contributed to early diagnosis of HCC. New nodules detected by ultrasonography can be confirmed with high specificity by the finding of arterial enhancement and portal venous or venous phase washout on dynamic contrast enhanced CT or MRI. The Barcelona Clinic Liver Cancer (BCLC) staging system stratifies HCC into stages of increasing severity each with its recommended treatment. The shortcoming of this staging is the heterogeneity of patients with intermediate stage disease, leading to a lack of uniformity in the treatments applied to these patients. Liver transplantation is associated with the best survival outcomes for patients with HCV-induced HCC, but graft loss can occur due to recurrence of chronic HCV in the transplanted liver. The 5-year survival of HCV-induced HCC after liver resection ranges from 40 to 70 %, but is marked by tumor recurrence rates of up to 75 % at 5 years, due to the development of de novo tumors in the residual cirrhotic liver. The best strategy to prevent HCV-induced HCC is to prevent HCV infection and to treat chronic infection at the earliest opportunity to mitigate the risk of progression to cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=84929910196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929910196&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-0870-7_5

DO - 10.1007/978-1-4939-0870-7_5

M3 - Chapter

AN - SCOPUS:84929910196

SN - 9781493908707

SN - 1493908693

SN - 9781493908691

VL - 9781493908707

SP - 87

EP - 112

BT - Viruses and Human Cancer

PB - Springer New York

ER -